IR-MED INC (IRME) Financials
Newest figures come from the 10-Q for Q2 FY2025, filed Aug 14, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IRME SEC filings page.
This page shows IR-MED INC (IRME) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
IR-MED INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
IR-MED INC's EBITDA was -$282K in Q2 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.3% from the same quarter a year earlier. Against the prior quarter it is down 12.8%.
IR-MED INC reported -$701K in net income in Q2 2025. This represents a decrease of 91.5% from the same quarter a year earlier.
IR-MED INC earned -$0.01 per diluted share (EPS) in Q2 2025. It is unchanged from the prior quarter.
Not reported for Q2 2025.
Cash & Balance Sheet
IR-MED INC held $63K in cash as of Q2 2025; long-term debt is not reported for that period.
Not reported for Q2 2025.
Not reported for Q2 2025.
Margins & Returns
None of these metrics is reported for Q2 2025.
Capital Allocation
IR-MED INC invested $91K in research and development in Q2 2025. This represents a decrease of 3.2% from the same quarter a year earlier. Against the prior quarter it is up 295.7%.
Not reported for Q2 2025.
Not reported for Q2 2025.
IRME Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $91K-3.2% | $23K-88.2% | N/A | $205K-56.3% | $94K-81.0% | $195K-67.8% | N/A | $469K+0.2% |
| SG&A Expenses | $194K-17.8% | $228K-22.7% | N/A | $367K-14.8% | $236K-46.6% | $295K-48.7% | N/A | $431K+12.2% |
| Operating Income | -$286K+20.1% | -$253K+61.6% | N/A | -$601K+49.8% | -$358K+67.5% | -$658K+51.3% | N/A | -$1.2M-36.6% |
| EBITDA | -$282K+20.3% | -$250K+61.5% | N/A | -$597K+50.0% | -$354K+67.6% | -$649K+51.9% | N/A | -$1.2M-36.8% |
| Net Income | -$701K-91.5% | N/A | N/A | -$598K+49.3% | -$366K+67.0% | -$657K+51.3% | N/A | -$1.2M-37.7% |
| EPS (Basic) | -$0.010.0% | -$0.010.0% | -$0.01+50.0% | -$0.01+50.0% | -$0.01+50.0% | -$0.01+50.0% | -$0.02+33.3% | -$0.02-100.0% |
| EPS (Diluted) | -$0.01 | -$0.010.0% | -$0.01+50.0% | -$0.01+50.0% | -$0.01 | -$0.01+50.0% | -$0.02+33.3% | -$0.02-100.0% |
| Diluted Shares (Avg) | 74M | 71M+1.9% | N/A | 71M+2.8% | 70M | 70M+1.6% | N/A | 69M+0.2% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
IRME Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $175K-80.3% | $124K-78.6% | $251K-74.9% | $533K-69.9% | $887K-66.2% | $579K-75.6% | $999K-69.7% | $1.8M-57.0% |
| Current Assets | $90K-88.6% | $81K-82.5% | $205K-75.8% | $443K-72.4% | $789K-67.6% | $463K-78.6% | $848K-72.3% | $1.6M-58.5% |
| Cash & Equivalents | $63K-91.6% | $51K-87.5% | $129K-83.2% | $392K-74.3% | $753K-67.8% | $408K-80.6% | $767K-74.5% | $1.5M-59.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $27K-25.0% | $30K-45.5% | $76K-6.2% | $51K-38.6% | $36K-63.6% | $55K-1.8% | $81K+47.3% | $83K0.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $800K+52.7% | $617K-7.2% | $545K-14.0% | $531K-5.3% | $524K-14.7% | $665K+1.8% | $634K-9.7% | $561K+2.9% |
| Current Liabilities | $774K | $617K | $545K+15.2% | N/A | N/A | N/A | $473K-28.5% | $559K |
| Non-Current Liabilities | $26K | $0 | $0-100.0% | N/A | N/A | N/A | $161K+302.5% | $2K-99.1% |
| Total Equity | -$625K-272.2% | -$493K-473.3% | -$294K-180.5% | $2K-99.8% | $363K-81.9% | -$86K-105.0% | $365K-85.9% | $1.2M-66.1% |
| Retained Earnings | -$18.2M-14.8% | -$17.5M-13.0% | -$16.7M-12.8% | -$16.5M-21.3% | -$15.9M-28.0% | -$15.5M-37.4% | -$14.8M-49.4% | -$13.6M-73.1% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
IRME Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$71K+80.9% | -$110K+69.3% | -$261K+65.4% | -$395K+51.3% | -$372K+51.5% | -$358K+60.2% | -$754K+3.2% | -$811K-20.0% |
| Depreciation & Amortization | $4K0.0% | $3K-66.7% | $4K | $4K0.0% | $4K-55.6% | $9K+125.0% | $0 | $4K0.0% |
| Stock-Based Compensation | $87K-13.0% | $54K-73.8% | N/A | $197K-48.6% | $100K-74.8% | $206K-56.9% | N/A | $383K+208.9% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $1K-50.0% | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$755K+3.3% | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$1K+50.0% | N/A |
| Financing Cash Flow | $88K | $31K | $0 | $35K | N/A | N/A | $0 | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
IRME Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | N/A | -29900.0%-29802.7pp | -100.8%-45.6pp | N/A | N/A | -97.3%-73.4pp |
| Return on Assets | -400.6%-359.3pp | N/A | N/A | -112.2%-45.7pp | -41.3%+1.0pp | -113.5%-56.6pp | N/A | -66.5%-45.7pp |
| Current Ratio | 0.12 | 0.13 | 0.38-1.4x | N/A | N/A | N/A | 1.79-2.8x | 2.87 |
| Debt-to-Equity | N/A | N/A | N/A | 265.50+265.0x | 1.44+1.4x | N/A | 1.74+1.7x | 0.46+0.4x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$294K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.38), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| IR-MED INC IRME | FY2024 | N/A | N/A | N/A | $231K | — |
| QHSLAB, INC USAQ | FY2025 | $2.7M | -$457K | -17.0% | $6.9M | — |
Where IR-MED INC Ranks
Frequently Asked Questions
What are IR-MED INC's total assets?
IR-MED INC (IRME) had $251K in total assets as of fiscal year 2024, including both current and long-term assets.
How much does IR-MED INC spend on research and development?
IR-MED INC (IRME) invested $710K in research and development during fiscal year 2024.
What is IR-MED INC's current ratio?
IR-MED INC (IRME) had a current ratio of 0.38 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Why is IR-MED INC's debt-to-equity ratio negative or not reported?
IR-MED INC (IRME) has negative shareholder equity of -$294K as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.